NCT05788601View on ClinicalTrials.gov

Dapiglutide for the Treatment of Obesity

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 27, 2023

Primary Completion Date

April 24, 2024

Study Completion Date

August 15, 2025

Conditions
ObesityInflammation
Interventions
DRUG

Dapiglutide

GLP-1/GLP-2 receptor agonism

DRUG

Placebo

Placebo

Trial Locations (1)

2900

Center for Clinical Metabolic Research, Herlev-Gentofte Hospital, Hellerup

Sponsors

Collaborators (1)

Zealand Pharma
All Listed Sponsors
collaborator

Zealand Pharma

INDUSTRY

lead

University Hospital, Gentofte, Copenhagen

OTHER

NCT05788601 - Dapiglutide for the Treatment of Obesity | Biotech Hunter | Biotech Hunter